Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
Quisovalimab by Avalo Therapeutics for Asthma: Likelihood of Approval
Quisovalimab is under clinical development by Avalo Therapeutics and currently in Phase II for Asthma. According to GlobalData, Phase II...
Data Insights
Risk adjusted net present value: What is the current valuation of Avalo Therapeutics's Quisovalimab?
Quisovalimab is a monoclonal antibody commercialized by Avalo Therapeutics, with a leading Phase II program in Crohn's Disease (Regional Enteritis)....